Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16858484 | 0.90 | TAS2R14 (0.64) | TAS2R14ALDH1A1TP53MAPTMMP3 | |
| SCHEMBL4656559 | 0.81 | ALDH1A1 (0.86) | TAS2R14ALDH1A1TP53MAPTMMP3 | |
| SCHEMBL4656751 | 0.80 | ALDH1A1 (0.66) | TAS2R14ALDH1A1MAPTMMP3THRB | |
| SCHEMBL15705617 | 0.79 | MAPT (0.65) | TAS2R14ALDH1A1MAPTTHRB | |
| SCHEMBL4655727 | 0.79 | ALDH1A1 (0.65) | TAS2R14ALDH1A1MAPTMMP3THRB | |
| SCHEMBL21315101 | 0.78 | NR1D1 (0.56) | TAS2R14ALDH1A1TP53MAPT | |
| SCHEMBL11575496 | 0.78 | TSHR (0.54) | TAS2R14ALDH1A1MCOLN3MAPTLMNA | |
| SCHEMBL13171948 | 0.78 | TP53 (0.58) | TAS2R14ALDH1A1TP53MAPTTHRB | |
| SCHEMBL16858555 | 0.77 | BMP1 (0.56) | TAS2R14 | |
| SCHEMBL21315083 | 0.77 | TAS2R14 (0.56) | TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015102929-A1 | TRICYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-07-09 | — | — | WO | disclosed |
| US-20150183802-A1 | TRICYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-07-02 | — | — | US | disclosed |
| US-20150183802-A1 | TRICYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-07-02 | — | — | US | disclosed |
| US-20150183802-A1 | TRICYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183802-A1 | TRICYCLIC SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, STS | TAS2R14 435/4885ALDH1A1 272/4885MCOLN3 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.